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Abstract: A mechanistic link between neuron-to-neuron transmission of secreted amyloid and
propagation of protein malconformation cytopathology and disease has recently been uncovered in
animal models. An enormous interest in the unconventional secretion of amyloids from neurons
has followed. Amphisomes and late endosomes are the penultimate maturation products of the
autophagosomal and endosomal pathways, respectively, and normally fuse with lysosomes for
degradation. However, under conditions of perturbed membrane trafficking and/or lysosomal
deficiency, prelysosomal compartments may instead fuse with the plasma membrane to release any
contained amyloid. After a brief introduction to the endosomal and autophagosomal pathways,
we discuss the evidence for autophagosomal secretion (exophagy) of amyloids, with a comparative
emphasis on Aβ1–42 and α-synuclein, as luminal and cytosolic amyloids, respectively. The
ESCRT-mediated import of cytosolic amyloid into late endosomal exosomes, a known vehicle of
transmission of macromolecules between cells, is also reviewed. Finally, mechanisms of lysosomal
dysfunction, deficiency, and exocytosis are exemplified in the context of genetically identified risk
factors, mainly for Parkinson’s disease. Exocytosis of prelysosomal or lysosomal organelles is a last
resort for clearance of cytotoxic material and alleviates cytopathy. However, they also represent a
vehicle for the concentration, posttranslational modification, and secretion of amyloid seeds.
Keywords: autophagosomes; α-synuclein; late endosomes; unconventional secretion; neurodegeneration
1. Introduction
The gradual decline of neuronal populations in protein malconformation brain disease is due to
the direct or indirect neurocytopathic effects of misfolded and aggregate-prone endogenous nerve
cell proteins. These disease-specific proteins include the prion protein (PrPsc) of Creutzfeldt-Jakob
disease, α-synuclein, which is the most abundant protein in Lewy Body inclusions of Parkinson’s
disease (PD), superoxide dismutase (SOD) in Amyotrophic Lateral Sclerosis, and in Alzheimer’s
disease (AD) hyper-phosphorylated tau makes up neurofibrillary tangles, while cleavage of amyloid
precursor protein (APP) causes parenchymal deposition of amyloid β peptide (Aβ) in the form of
amyloid plaques [1]. Despite lack of sequence homology, these proteins form aggregates in the
form of oligomers and fibrils, which present a similar pathological folding epitope consisting of a
“steric zipper” of β-pleated sheets [2], and they are in a sense self-replicating if enough monomer
protein is present to sustain misfolding and the aggregation cascade [1]. For the extent of this
review, we will use the term amyloid to refer to multimeric proteinaceous assemblies with distinctive
histochemical features in tissues, and a cross-β quaternary structure as determined by X-ray fibre
diffraction analysis [1]. Different species of oligomers and fibrils of any specific amyloid can exert
neurotoxicity by different mechanisms, and multiple inoculating species of each amyloid are capable
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of propagating the disease [3,4]. Nerve cells will suffer from intracellular protein aggregation, as well
as pathological interference by secreted species of amyloid mainly in soluble oligomer form [5–7],
but also fibrils [8]. Typical neurocytopathic features of intracellular protein aggregation includes
inhibition of degradative systems (autophagolysosomal pathway and the proteasome), development
of Endoplasmatic reticulum (ER)-stress, and induction of mitochondrial and cytosolic oxidative stress,
which, if sustained, result in nerve cell death.
In the following we will first briefly discuss seeded conversion and transmission of amyloid
proteopathy, and the basic working of the endosomal and autophagosomal pathways, before we finally
delve into the trafficking of prelysosomal organelles and their possible role in secretion of amyloid and
propagation of amyloid proteopathy in the brain.
2. Seeded Conversion and Transmission of Amyloid Proteopathy In Vivo and In Vitro
2.1. Seeded Conversion
Amyloid formation has almost universally been shown to involve a nucleation-dependent
polymerization reaction [1,9], which also describes well-characterized biological processes such
as microtubule assembly and actin polymerization. First, a so-called nucleus forms from a few
assembled monomers in a misfolded state. This initial step is highly thermodynamically unfavorable
and is rate limiting for amyloid growth. Once a nucleus has emerged, it catalyzes, in a prion-like
fashion, the seeded conversion of endogenous, monomeric protein into a pathological conformational
state, which is competent for polymerization into oligomers and then fibrils provided sufficient
monomeric, wild type protein is present [1,4,9–11]. As such, seeded conversion is the driving force
of template-dependent propagation of amyloids in the brain. Total amyloid growth is accelerated by
secondary nucleation events caused by fibril breakage, which generates more free ends for templating
and polymer growth [10–12]. Each of the three microscopic steps of aggregate formation, namely
nucleation, fibril growth, and fibril amplification, is to a different degree influenced by environmental
factors such as lipid bilayers [11] and pH [12], as well as by disease-causing mutations [11]. The kinetic
reactions are very complex to solve analytically and only recently has it been possible to design a
toolkit for the mathematical description of filament nucleation and growth. The results underpin the
long lag phase for aggregate formation, reflecting the rare event of nucleation, and the accelerated
amyloid growth obtained by fragmentation and secondary nucleation [10]. Although a description
of the seeding process is approaching, the underlying mechanism(s) of amyloid formation is still
being debated.
Each given amyloid may adopt distinct conformational states resulting in fibrils with different
structural, chemical, and pathological properties [13–16]. The molecular composition and conformation
of specific amyloid strains can be maintained by seeded conversion both in vitro and in vivo [17].
For each patient one strain dominates the pathology, dictated by the rarity of the nucleation event [14],
which likely contributes to the diverse clinical manifestations of AD and PD in patients. In mouse
models one species of amyloid can influence aggregation of other amyloids, a phenomenon referred
to as cross-seeding, and this precipitates a particularly rapidly progressing neurodegeneration
in vivo [18,19]. The results are relevant to the development of PD-associated dementia, part of which,
is most likely caused by incipient AD [20].
2.2. The Unit Operations: Release, Transmission, and Uptake
Within the past few years, an additional layer of knowledge has been added to our understanding
of protein malconformation brain disease. Evidence gained from research in cultured nerve cells and
from experimental mouse models of AD, PD, and tauopathy indicates that these neurodegenerative
diseases spread in the brain by the transcellular relay (transmission) of amyloid protein in possibly
multiple inoculating forms [21], from neuron to neuron [1,4,22–24]. Secreted amyloid from an
affected neuron can gain entry into the cytosol of a neighbouring neuron (or glia cell for that matter),
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and function as a proteopathic template for recruitment of endogenous protein monomers into the
pathological cascade of protein misfolding and aggregation.
Our knowledge about the cellular and molecular mechanisms that mediate critical unit
operations of the proposed transmission model of proteopathy is clearly lagging behind the strong
phenomenalistic evidence from animal models. Unit operations must, as a minimum, include secretion
of amyloid from donor cell to extracellular milieu, intercellular transfer, and finally, entry into recipient
cell cytosol to initiate templated protein misfolding and perpetuation of disease.
The release of Aβ1–42 from nerve cells following proteolytic cleavage of the APP membrane
protein, and the secretion of PrPsc from infected cells, have been recognized for long, but more recently
secretion of cytosolic amyloid species from cultured nerve cells has been documented for tau [25,26],
α-synuclein [27–33] and SOD [34,35].
A growing number of in vitro studies have demonstrated the potential of monomeric, oligomeric,
and/or fibrillary forms of amyloid to be taken up by neurons in culture, including α-synuclein [36–40],
tau [41,42], Aβ1–42, and SOD [43]. While monomeric species of amyloid may pass membranes
passively [39], there is evidence of active endocytic uptake mechanisms for aggregated tau [41,42] and
α-synuclein species in nerve cells [37–39]. At least α-synuclein uptake can be blocked by dynamin
inhibition [37–39] suggesting receptor-mediated uptake trough pinocytic routes, although, at least one
study indicated a dynamin-independent entry route [44]. Aggregated SOD is potentially internalized
via macropinocytosis [43]. Heparan sulphate proteoglycans on the surface of cells may bind amyloids
for internalization, or more likely, transfer amyloid to an internalization receptor for entry akin to
virus internalization [45]. However, no internalization receptors for amyloid have been defined in
neurons, although surface receptors are known [46]. In contrast, microglia, the supportive glia cells
and resident macrophages of the brain [47], express a number of immune cell receptors, which have
been implicated in the uptake of amyloids into microglia and/or inflammatory activation of microglia.
Some of these receptors e.g., Fc-γ receptors for IgG (FcγR) and Toll-like receptors (TLRs) are also
expressed at lower levels in neurons. In microglia α-synuclein is internalized by TLR4 [48,49] and
perhaps FcγR [50], while activation (cytokine production) of microglia depends on TLR2 [51,52] and
potentially FcγR’s [50,53]. In addition, morphological changes and chemotactic response of microglia
towards aggregated α-synuclein is mediated through CD11b (integrin α2) [54] and β1 integrins [55].
In the context of AD many different receptors have been implicated in immune cell activation and
internalization of Aβ1–42 by microglia including scavenger receptor, receptor for advanced glycation
endproducts (RAGE), CD36 in a complex with CD47 and α6β1 integrin, CD14, CD11b/CD18 (α2βm),
and TLR2 and 4 [56–67]. Uptake might be either pinocytic or macropinocytic [68], and uptake of
exosome-associated Aβ1–42 has been reported [69].
In vitro and in vivo experiments demonstrate interneuronal transmission of endogenously
produced and secreted α-synuclein [27,36,37,40,70–72], tau [25,41,73–76], SOD [35,43], or
Aβ1–42 [3,21,77–80]. In a number of the in vitro studies transmitted amyloid was found to seed
aggregation and cytosolic inclusions of endogenous wild type protein in the acceptor nerve cells,
and cytopathy could be propagated for extended passages [25,36,40,41,43,81]. A few reports on
transmission of α-synucleinopathy with Lewy Body disease from host cells to engrafted fetal neurons
in human PD have been published [70,82,83].
2.3. In Vivo Transmission of Proteopathic Amyloids
A series of simple in vivo experiments have provided solid evidence for the transmission of
proteopathic amyloids in the brains of wild type or transgenic mice. Early experiments described the
ability of brain homogenates containing pathological Aβ aggregates to inoculate cerebral amyloidosis
following injection into the brains of APP transgenic mice [3,21,78,84]. Recently, propagating AD- or
PD-like pathology and neurodegeneration in mouse brain were achieved by injection of purely in vitro
preformed, recombinant Aβ1–42 or α-synuclein aggregates, respectively [71,72,80]. In a similar venue
focal expression of mutant tau in mouse entorhinal cortex caused propagation of tau pathology
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to other anatomically interconnected brain areas along nerve fiber tracts [76], and injection of tau
aggregates into the brain of nontransgenic mice is sufficient to precipitate propagating tau inclusion
disease [85]. These experimental findings are in good agreement with the longstanding observation
that spread of AD and PD pathology in the human brain follows a mainly stereotypical pattern along
fiber tracts as delineated by Braak and colleagues [1,20,22,86]. Most recently, detailed analysis of
the temporal progression of aggregation disease through synaptically connected neurons in wild
type mice receiving α-synuclein fibril injections into the olfactory bulb has been presented in a new
model of synucleinopathy, which may mimic aspects of prodromal PD [87]. Injection of brain extracts
containing Aβ1–42 into the peritoneal cavity of mice inoculates vascular β-amyloidosis in the brain [78],
and recombinant α-synuclein injected into peritoneum or blood stream finds its way to the brain
parenchyme [8] demonstrating the potential of amyloids, other than PrPsc, for retrograde trafficking to
the brain from the periphery. In the case of PD there is evidence that environmental toxin-induced
α-synuclein misfolding can start in the enteric nervous system followed by retrograde transport of
amyloids via the vagus nerve to the central nervous system [88].
Of the different amyloids only PrPsc is considered a truly infectious agent as it can be passed
between individuals (cannibalism) and even species (transmission of mad cow disease) after oral
ingestion to inoculate disease in the recipient. It should be noted however, that retrospective studies
of patient cohorts that received cadaveric pituitary growth hormone and became infected with
Creutzfeldt-Jakob disease, also demonstrate a high proportion of AD pathology in the brain, indicating
that both diseases were transmitted to the recipient [89].
After a short introduction of the endosomal and autophagosomal pathways, we will discuss the
potential role of late endosome and amphisome exocytosis in the dissemination of proteopathic species
of amyloid, with an emphasis on α-synucleinopathy.
3. The Endosomal Pathway
Early endosomes are the primary recipient organelle of endocytosed membrane lipid and protein.
From early endosomes, which morphologically appear as tubulovesicular elements, the majority
of internalized membrane and receptors are recycled to the plasma membrane within 20 min by
direct and indirect sorting pathways [90]. During this time the bulk of the early endosome receives
defining molecules by vesicular trafficking or binding of cytosolic factors to the endosome membrane
that govern the gradual molecular maturation into a late endosome. Such molecules include Rab7,
homotypic fusion and protein sorting (HOPS) complex, phosphatidylinositol 3-phosphate kinase
(PI3K), endosomal sorting complexes required for transport (ESCRT)-0 and -I, Vacuolar Adenosine
Triphosphatase (v-ATPase), and the mannose-6-phosphate receptor (M6PR). In addition, the endosome
matures morphologically: membrane proteins, such as the epidermal growth receptor destined
for degradation in lysosomes, are removed from the recycling pathway by a process of inward
budding of the limiting endosomal membrane. This process forms multivesicular bodies (MVBs;
a morphological term including late endosomes) containing intraluminal vesicles (ILVs) enriched
by a receptor-mediated process for certain lipids and proteins [91,92]. The cargo is mainly destined
for degradation in lysosomes, but a minor proportion will be released from cells by late endosome
exocytosis. After secretion, ILVs are by convention termed exosomes, which, by their receptor-mediated
inclusion of cytosolic cargo, can carry biological information (RNA) or even function (protein) between
cells [93–95].
3.1. ESCRT-Dependent and -Independent Loading of Intraluminal Vesicles (~Exosomes)
Import of many protein cargoes into ILVs is dependent on mono- or poly-(with a preference
for K63-linked) ubiquitinylation and is mediated by four cytosolic multi-component protein
assemblies localized on the surface of MVBs called endosomal sorting complexes required for
transport (ESCRT0-III) [92,96]. ESCRT-0 subunits hepatocyte growth factor-regulated substrate
(Hrs)/signal-transducing adaptor molecule (STAM) are required for cargo selection and sorting. The
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functions of ESCRT-I and -II are more uncertain despite the presence of ubiquitin-binding domains [97]
and may reside in the recruitment of ESCRT-III. This last complex is required for ILV abscission from
the MVB membrane through recruitment of the AAA+ ATPase Vps4. But first, or concomittantly,
ESCRT-III and Vps4 mediate de-ubiquitination of cargo and dissolution of the ESCRT complexes
for new rounds of sorting [92,96]. Hrs of ESCRT-0 [98] and Vps proteins of ESCRT-III participate in
different kinds of, potentially cargo-organized, protein lattices on the cytosolic side of the limiting
membrane, which perhaps function in the receptor-mediated sequestration of lipids and proteins
to be sorted [96]. Syndecan heparan sulphate proteoglycans and their cytosolic adaptor syntenin
transfer cargo to the ESCRT machinery for sorting into ILVs in an Adenosine diphosphate-ribosylation
factor 6 (ARF6) and phospholipase D-regulated mechanism [27,99–102]. Other examples of accessory
proteins that can feed ubiquitinated substrate into the ESCRT pathway are known including the yeast
orthologue of Alix [103].
Notably, other forms of sorting platforms formed by either ceramide or tetraspanins also function
in the sorting to and formation of ILVs [91,104,105]. These ESCRT-independent sorting platforms
seem to recruit cargo solely on the basis of biophysical properties such as aggregation, membrane
association, and recruitment to cholesterol- and sphingolipid-enriched membrane microdomains [106].
The ESCRT-dependent and -independent mechanisms of ILV formation give rise to ILV populations of
different sizes [107].
3.2. Final Endosome Maturation
The subtractive and additive trafficking of lipids and membrane proteins results in the gradual
molecular and morphological maturation of the early endosome into a mature late endosome, which
finally fuses with lysosomes for degradation of its luminal contents including ILVs. The fusion process
is regulated by HOPS, which promotes tethering and fusion of membranes through interaction with
the soluble N-ethylmaleimide-sensitive factor-attachment protein receptors (SNARE) fusion machinery.
Specific SNAREs, including Vesicle transport through interaction with t-SNAREs homolog 1B (Vti1b),
and syntaxins 7 and 8 on late endosomes, engage with the lysosomal SNARE vesicle-associated
membrane protein (VAMP)8 to make up the trans-complex that mediate fusion of endosomes with
lysosomes. The same Q-SNAREs can engage with VAMP7 to mediate preferentially homotypic fusion
of late endosomes [108].
However, a minor proportion of MVBs/late endosomes may instead fuse with the plasma
membrane under physiological conditions to release the luminal contents to the surroundings
(see below). It is not known whether these exocytic MVBs constitute a specified subpopulation, but
different forms of perturbation of the endocytic pathway or lysosomal deficiency increases secretion of
exosomes [27,101,102].
4. The Autophagosomal Pathway
Autophagy is a lysosomal degradation pathway, which is responsible for the removal and
degradation of cytosolic cargo including protein aggregates, long-lived proteins, and worn-out
organelles and macromolecules [109–112]. Basal autophagy is cytoprotective and essential for neuronal
function and survival because of the post-mitotic status of neurons (accumulated material cannot be
diluted by cell division) [113,114]. However, autophagic flux can be increased further in response to
either intracellular stress in the form of nutrient depletion, reactive oxygen species, mitochondrial
dysfunction, ER-stress, and accumulation of certain cytosolic protein aggregates [109], or different
kinds of external cues including pathogen invasion and inflammation [115].
In the following we will discuss macroautophagy (henceforth referred to autophagy), the
autophagic mechanism quantitatively most important for the bulk disposal of macromolecular cargo.
However, other forms of autophagy including micro-autophagy [116], and chaperone-mediated
autophagy [117], which deliver autophagosomal substrates directly to the lysosome without vesicular
autophagosome intermediates, are also relevant in the context of neurodegenerative disease.
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4.1. Autophagosome Nucleation
An autophagosome is formed by the sequestration of a volume of cytosol by a double or
multi-layered membrane [112,118]. The autophagosome is born as a phosphatidylinositol 3-phosphate
(PI3P)-specified domain in conjunction with the ER called an omegasome because of its cradle-like
structure [119,120]. Initiation is governed by the ser/thr-kinase uncoordinated family member-51-like
kinase (ULK1/ULK2) initiator complex, which regulates a multiprotein complex containing Beclin-1
(Atg6), Atg14, and Vps34 (PI3K-III) with regulatory sub unit p150. PI3K activity is required for
association of PI3P effectors, which in turn recruit essential autophagy machinery for nucleation
of the omegasome [121]. The cellular growth regulator mammalian target of rapamycin (mTOR;
inhibition of ULK) and the cellular energy charge sensor AMP-activated protein kinase (AMPK;
activation of ULK) controls the ULK complex and autophagy initiation [109,110]. The omegasome
develops by addition of membrane derived mainly from the ER lipid pool [119–121] into a so-called
phagophore (also called isolation membrane). Also mitochondria, the Golgi apparatus, and the
plasma membrane/early endosomes constitute reservoirs of lipid and membrane for the nascent
autophagosomal organelle [122–128]. These organelles can be seen making contacts with the
phagophore, sometimes multiple organelles at once [129]. Actin nucleation is required for formation
and expansion of the omegasome and phagophore [130], and is likely also required at later stages of
autophagy [131,132].
Elongation and expansion of the phagophore is regulated by a host of conserved ATG gene
products [110] including the two protein conjugation systems Atg5-Atg12-Atg16L and Atg8.
Conjugation of Atg5-Atg12 to autophagosomes is transient. In contrast, Atg8 homologues, consisting
of two families defined by microtubule-associated protein 1 light chain 3 (LC3) and GABAA
receptor-associated protein (GABARAP) are conjugated to phosphatidylethanolamine in both
the inner and outer autophagosome membrane. LC3 and GABARAP remain associated with
autophagosomes up to and including autolysosomes, making LC3 a commonly used marker of
autophagosomes [112,118,133]. LC3 and GABARAP are required for phagophore expansion [133,134]
where the membrane is delivered de novo, but also by the SNARE-regulated fusion of
Atg9- or Atg16L-positive vesicles derived from the plasma membrane and the early endosome
compartment [123–126,135]. Autophagosome precursors grow further in size by homotypic fusion in
a SNARE-regulated process [136]. GABARAP acts at a later stage of autophagosome maturation than
LC3 and influences autophagosome membrane closure [134], cargo sequestration [137], as well as
final fusion with endolysosomes [138]. The six mammalian LC3/GABARAP homologues interact
with a cohort of accessory proteins, some of which are carriers of autophagosomal cargo (see selective
autophagy below), while others are regulators of the autophagosomal pathway [139].
Non-canonical forms of macroautophagy that work independently of one or more ATG
gene products are known [127,140,141], as are mTOR-independent pathways of autophagy
induction [142–144].
Selective Autophagy
Whereas starvation-induced autophagy indiscriminately engulfs, degrades, and recycles
cytoplasmic constituents for anabolic reactions, selective autophagy, also called quality-control
autophagy, accepts preferentially ubiquitinylated cargo. A number of autophagy receptors including
p62/SQSTM1 [145] and SQSTM1-related proteins such as Neighbor of BRCA1 gene 1 (NBR1),
optineurin, and Nuclear domain 10 protein 52 (NDP52) [146] bind poly-ubiquitinated cargo as well as
LC3 and other Atg8 proteins thereby selectively recruiting ubiquitinated substrates to the phagophore
for sequestration [147]. Autophagy receptors unrelated to p62 are also known [148]. These autophagy
receptors are essential for the ability of cells to clear cytosolic protein aggregates. The proteasome also
accepts ubiquitinylated cargo, and adaptor proteins like histone deacetylase 6 (HDAC6) [149] and Bcl-2
associated athanogene (BAG) proteins [150] are required for shuttling cargo to the autophagosome
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pathway during conditions of depressed proteasome activity or increased protein misfolding and
ER-stress [111].
4.2. Autophagosome Maturation
The final destination of the contents enclosed by the autophagosome is the lysosome through the
formation of an autolysosome. While this direct fusion event can occur, it has been recognized for some
time that autophagosomes mature mainly by first fusing with endosomal compartments, including
early (recycling), and in particular, late endosomes, before final fusion with lysosomes [151–153].
The hybrid compartment thus formed is termed an amphisome, which contains both cytosolic material
taken up by autophagy as well as endocytic cargo including ILVs. It is therefore not surprising that
many of the factors that govern autophagosome maturation and fusion with lysosomes derives from
the endocytic pathway.
Autophagosome Mobility
Autophagosome transport depends on intact microtubules [154] and functional dynein-dynactin
motors [155]. In nerve cells, most autophagosomes are formed distally in the neuritic network,
which contains the bulk of the cytosol, and then transported retrogradely along microtubuli while
maturing towards the cell soma where lysosomes are concentrated [156,157]. In this respect, the fusion
of autophagosomes with late endosomes is functionally required for the amphisomal acquisition
of dynein motor protein, and inhibition of fusion by syntaxin17 knock-down results in the axonal
accumulation of autophagosomes [158]. By hooking up with different adaptors (Rab-interacting
lysosomal protein (RILP) or FYVE and coiled-coil domain-containing protein 1 (FYCO)), Rab7 regulates
plus- or minus-end directed motility of amphisomes and late endosomes on microtubule tracks through
interactions with dynein-dynactin and kinesin motors, respectively [159–164]. Autophagosomes are
decorated with both kinesin and dynein motors indicating that either motor can be silenced for
vectorial transport [156]. HDAC6 binds polyubiquitin and dynactin, and is essential in the retrograde
trafficking of ubiquitinated protein aggregates and organelles towards the cell center [165,166].
4.3. Autophagosome Fusion with Endolysosomes
Within the past few years, many groups have contributed novel insight into the identity of
SNAREs required for fusion of autophagosomes with endosomal or lysosomal membranes, and the
factors that regulate the fusion machinery (see Figure 1). Often the distinction between autophagosome
fusion with late endosomes or lysosomes is not explicitly addressed experimentally, which is why many
of these fusion factors are described as controlling entry into endolysosomes (meaning late endosomes
and lysosomes). Nevertheless, the distinction is important. As we shall see, different conditions
and different SNAREs are required for exocytosis of prelysosomal versus lysosomal elements, which
becomes relevant in the context of disease-associated perturbations of the maturation pathways.
The fusion of autophagosomes with endosomes and the fusion of amphisomes with lysosomes is
regulated by Rab7 [159,167–169], a central guanosine triphosphatase (GTPase) in the control of late
endosome and lysosome mobility, distribution, and fusion [164,170,171]. An important Rab7 effector
is the HOPS complex. Failure to recruit Rab7 to prelysosomal elements, pharmacologically obtainable
by thapsigargin treatment, causes a block of autophagosome fusion with lysosomes [168].
The enzymatic activity of phosphatidylinositiol 4-phosphate kinase II (PI4KII) regulates the fusion
between autophagosomes and late endosomes to form amphisomes [138]. GABARAP is required
for recruitment of PI4KII, which generates phosphatidylinositol 4-phosphate (PI4P) on the surface of
autophagosomes. Deficiency of the kinase or PI4P on the autophagosome specifically blocks fusion
of autophagosomes with late endosomes as a double-layered membrane surrounds the organelles
accumulating under these conditions [138]. The role played by PI4P for entry into the degradative
endolysosomal compartment is currently unknown.
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Figure 1. Entry of autophagosomes into the endolysosomal system. The closed autophagosome is 
contained by two membranes, which allows the ultrastructural distinction of autophagosomes from 
any other organelle, as the outer membrane is lost upon the first fusion reaction. The 
autophagosomal Soluble N-ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) 
syntaxin17 and Atg14, which both influence later fusion reactions, are present on the phagosome 
Phosphatidylinositol 4-kinase (PI4K)II and its lipid product phosphatidylinositol 4-phosphate (PI4P) 
is specifically required for autophagososomes and late endosomes to form the hybrid organelle, an 
amphisome, in a fusion reaction mediated by Homotypic fusion and protein sorting (HOPS) and 
syntaxin17/Synaptosomal-associated protein (SNAP)29. Atg14 may primarily exert its function also 
at this stage. The subsequent fusion with lysosomes is also dependent on HOPS and 
syntaxin17/SNAP29, which partner up to form fusion competent trans-SNARE complexes with 
lysosomal SNARE Vesicle-associated membrane protein (VAMP)8. Alternative SNAREs for this 
fusion reaction are potentially v-SNARE Vesicle transport through interaction with t-SNAREs 
homolog 1B (Vti1b) and t-SNARE VAMP7. A number of factors have recently been identified that 
promote syntaxin17/SNAP29/VAMP8 interactions in different forms. ATG14 binds syntaxin17 
directly, while Microtubule-associated proteins 1A/1B light chain 3B (LC3B) recruits both Pleckstrin 
homology domain-containing family M (PLEKHM) and Ectopic P-Granules Autophagy Protein 5 
Homolog (EPG5) to the autophagosome. Here EPG5 (3) stabilizes the trans-SNARE complex with 
VAMP8, while PLEKHM (1) and ATG14 (2) interact with the bivalent SNARE pair 
syntaxin17/SNAP29. 
Syntaxin-17 is a SNARE that works exclusively in the autophagosomal pathway, where it 
participates in HOPS-catalyzed membrane fusion reactions. Syntaxin-17 has a unique double hairpin 
structure for insertion into the limiting membrane of the autophagosome, and mediates fusion with 
late endosomes and lysosomes in a VAMP8 and human synaptosomal-associated protein 29 
(SNAP-29) regulated mechanism [172–175]. In flies, syntaxin-17 deficiency causes neurodegeneration 
due to the accumulation of autophagosomes [176]. Syntaxin-17 or SNAP29 deficiency in mammalian 
cells, and C-VPS/HOPS deficiency in drosophila, causes the accumulation of non-degradative 
autophagosomes, many of which still have a two-layered membrane, which suggests that 
Figure 1. Entry of autophagosomes into the endolysosomal system. The closed autophagosome is
contained by two membranes, which allows the ultrastructural distinction of autophagosomes from
any other organelle, as the outer membrane is lost upon the first fusion reaction. The autophagosomal
Soluble N-ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) syntaxin17 and Atg14,
which both influence later fusion reactions, are present on the phagosome Phosphatidylinositol 4-kinase
(PI4K)II and its lipid product phosphatidylinositol 4-phosphate (PI4P) is specifically required for
autophagososomes and late endosomes to form the hybrid organelle, an amphisome, in a fusion reaction
mediated by Homotypic fusion and protein sorting (HOPS) and syntaxin17/Synaptosomal-associated
protein (SNAP)29. Atg14 may primarily exert its function also at this stage. The subsequent fusion
with lysosomes is also dependent on HOPS and syntaxin17/SNAP29, which partner up to form fusion
competent trans-SNARE complexes with lysosomal SNARE Vesicle-associated membrane protein
(VAMP)8. Alternative SNAREs for this fusion reaction are potentially v-SNARE Vesicle transport
through interaction with t-SNAREs homolog 1B (Vti1b) and t-SNARE VAMP7. A number of factors
have recently been identified that promote syntaxin17/SNAP29/VAMP8 interactions in different
for s. ATG14 binds syntaxin17 directly, while Microtubule-associated proteins 1A/1B light chain
3B (LC3B) recruits both Pleckstrin homology domain-containing family M (PLEKHM) and Ectopic
P-Granules Autophagy Protein 5 Homolog ( PG5) to the autophagosome. Here EPG5 (3) stabilizes
the trans-SNARE c mplex wit VAMP8, while PLEKHM (1) and ATG14 (2) interact with the bivalent
SNARE pair syntaxin17/SNAP29.
Syntaxin-17 is a SNARE that works exclusively in the autophagosomal pathway, where it
participates in HOPS-catalyzed membrane fusion reactions. Syntaxin-17 has a unique double hairpin
structure for insertion into the limiting membrane of the autophagosome, and mediates fusion with
late endosomes and lysosomes in a VAMP8 and human synaptosomal-associated protein 29 (SNAP-29)
regulated mechanism [172–175]. In flies, syntaxin-17 deficiency causes neurodegeneration due to the
accumulation of autophagosomes [176]. Syntaxin-17 or SNAP29 deficiency in mammalian cells, and
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C-VPS/HOPS deficiency in drosophila, causes the accumulation of non-degradative autophagosomes,
many of which still have a two-layered membrane, which suggests that syntaxin-17-SNAP29-VAMP8
interactions are primarily involved in fusion of autophagosomes with late endosomes [172,177].
Syntaxin17 also binds v-SNARE Vti1b and t-SNARE VAMP7 [172], and has been described to engage
with endolysosomal VAMP7/SNAP29 in a HOPS-mediated fusion reaction of autophagocytosed
mitochondria with endolysosomes [178]. The alternative SNARE Vti1b is involved in homotypic fusion
of smaller autophagosome precursors [136], but also contributes at late stages of canonical autophagy
and xenophagy (autophagy of pathogens) by pairing up with lysosomal VAMP7 to mediate fusion [173].
Vti1b may function at a later stage than syntaxin-17 as Vti1b deficiency causes accumulation of both
autophagosomes and amphisomes (with a mild penetrance in knock-out mice) [179].
The nutrient sensor mTOR regulates autophagy induction, but also the SNARE machinery
involved in autophagosome-lysosome fusion is directly sensitive to cellular nutrient status. Thus,
SNAP-29 is O-glycosylated in fed cells, which results in a diminution of its ability to mediate lysosomal
membrane fusion, a phenomenon which is reversed upon starvation and deglycosylation [180].
Curiously, syntaxin-17 is also present on the phagophore [120]. As it turns out, two other ATG
gene products, namely Atg14 and Atg17, participate in both phagophore nucleation as well as in fusion
events at the level of autophagosome entry into the endolysosomal system.
Thus, in mammalian cells Atg14, an essential subunit of the Beclin-PI3K complex at the
point of nucleation and expansion [181,182], has a secondary role at the stage of fusion with
late endosomes by binding and priming the bivalent syntaxin17-SNAP29 SNARE complex for
interaction with endolysosomal VAMP8 [183]. In contrast, stabilization of the full trans-SNARE,
syntaxin17-SNAP29-VAMP8 complex, seems to reside with the Ectopic P-Granules Autophagy
Protein 5 Homolog (EPG5), which tethers Syntaxin-17/SNAP29 to VAMP8 present on lysosomes [184].
Dimerized Atg14 binds directly to the core domain of syntaxin-17 [183], whereas EPG5 and another
recently identified fusion regulatory protein, human pleckstrin homology domain-containing family
M member (PLEKHM), are recruited to autophagosomes by LC3 binding [184,185].
Lastly, Atg17, in complex with other Atg proteins, acts at the stage of autophagy induction in yeast,
but is also necessary for down-stream recruitment of the vacuolar SNARE Vacuolar morphogenesis
protein 7 (Vam7), which mediates fusion with the yeast vacuole [186]. It remains to be seen whether
this finding translates into the mammalian system.
It is at present unclear whether syntaxin17, potentially Vti1b, Atg14, or Atg17 activity is
regulated as they remain with the maturing autophagosome, or whether they undergo dynamic
dissociation/association cycles. The latter may pertain to syntaxin17 [172]. As Atg17 binds with
Vamp7 to inhibit its SNARE activity, it is possible in this case, that down-stream posttranslational
modification liberates SNAREs for function at the stage of fusion with endolysosomes [186].
The HOPS complex is a SNARE-interacting complex mediating membrane tethering and fusion
reactions of late endosomes and amphisomes with lysosomes. In yeast, all membrane fusions with
the vacuole (lysosome) are controlled by the c-VPS/HOPS complex, which also occupies a dominant
regulatory node in mammalian membrane traffic [187]. HOPS has been identified as a binding
partner for syntaxin-17, and all subunits of HOPS are required for clearance of autophagosomes in
drosophila [176,177]. Embedded in different subunits, the HOPS complex has both Rab7 guanine
nucleotide exchange factor activity, as well as Rab7 effector function. Rab7 is an important recruiter of
HOPS to the limiting membrane, and RILP, a Rab7 effector and guardian of late endosomal structure
and function [161], also recruits HOPS to late endosomes independently of Rab7 [188].
A mutation (D251E) of the HOPS subunit VPS33A, responsible for v/t-SNARE ligation, causes
locomotor defects and purkinje cell death in mice (buff mutant mice). The mutation seemingly increases
the affinity of HOPS interactions with the trans-SNARE complex of syntaxin-17/SNAP29/VAMP8 in a
way that hinders fusion of autophagosomes with endolysosomes [189]. This study found endosomal
trafficking to lysosomes to be unperturbed, and similarly, others have found that VPS16 subunit
deficiency specifically affects the autophagosomal but not the endocytic maturation pathway [168].
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In contrast, other groups find a dual block in both maturation pathways following deficiency of
any HOPS subunit in mammalian cells [187] as well as drosophila [177] in line with the dominant
regulatory role of HOPS in yeast.
Two different protein factors co-ordinately regulate the progression of autophagosomes and
endosomes through the maturation pathway by modulating Rab7 and HOPS function. Beclin-1, present
in the ULK initiator complex bound to ATG14L, can engage in alternative binding reactions with either
UV radiation resistance-associated gene protein (UVRAG) [159] or Run domain Beclin-1-interacting
and cysteine-rich domain-containing protein (Rubicon) [181,182], which mediate a positive or
negative influence on autophagosome (and endosome) maturation, respectively. UVRAG, which
displaces ATG14L from the initiator PI3K complex, interacts with the HOPS complex to stimulate
Rab7 GTPase activity [159] and PI3K activity [182], and promote autophagosome fusion with late
endosomes/lysosomes. UVRAG can be sequestered from the PI3K complex by Rubicon, which
therefore acts as a negative regulator of endosomal and autophagosomal flux [160,170,181].
The terminal maturation of autophagosomes and/or amphisomes also requires ESCRT
subunits [190]. Both in drosophila and mammalian cells, deficiency of ESCRT subunits causes a
dramatic accumulation of autophagosomes, correlating with cytotoxicity, due to reduced endosomal
and lysosomal fusion [191–193]. The requirement for ESCRT and HOPS subunits likely reflects the
need for a continuous and uninterrupted flux of late endosomes/MVBs for fusion availability with
autophagosomes [177,193].
PLEKHM, which was identified as an interaction partner of LC3B in the yeast two-hybrid
system [139], has been shown to interact with the HOPS complex [185]. PLEKHM associates with
Lysosome-associated membrane protein (LAMP)1-positive endolysosomes in resting conditions,
and mediates vesicle tethering and autolysosome fusion reactions in interplay with Rab7
and Syntaxin17-SNAP29. Deficiency of PLEKHM inhibits degradation of both endocytic and
autophagosomal cargo [185].
Fusion of autophagosomes with lysosomes requires reorganization of the local actin network.
This function is upheld by HDAC6, which controls the actin modulating protein cortactin through
deacetylation [194]. We have recently described that tubulin polymerization promoting protein
(TPPP/p25α), a protein ectopically expressed in dopaminergic neurons in PD, blocks amphisome
fusion with lysosomes [29], most likely by its ability to inhibit the deacetylase activity of HDAC6 [195].
5. Amyloids Are Substrates of the Autophagosomal Machinery
Pathological protein aggregates in the cytosol, including α-synuclein, are removed and degraded
by the ubiquitin-proteasome system and different forms of autophagy [196–198]. Several studies have
shown that pathological forms of α-synuclein [117,142,196,197,199], huntingtin [142,200–202], and
tau [203–206] are substrates of the chaperone-mediated and the macro-autophagosomal pathways.
Even though APP/Aβ is membrane-bound/luminal, the cellular levels of these proteins is in
part regulated by autophagy [207], although this contention has been challenged [208]. Recent
studies in mouse models of AD with Atg7 deficiency support a role of autophagy in secretion
of Aβ1–42 and deposition of amyloid plaques [209]. It is conceivable that Aβ1–42-containing
endosomes and/or lysosomes are dysfunctional and damaged, and as such become sequestered into
autophagosomes [210,211].
While α-synuclein is taken up by both macroautophagy and chaperone-mediated autophagy,
modified or aggregated forms of α-synuclein have also been found to partially inhibit the very same
pathways in different neurodegenerative disease models [117,196,197,199,212,213]. The mechanisms
range from inhibition of autophagosome formation [208,212,214,215], inhibition of cargo loading in
selective autophagy [202] or chaperone-mediated autophagy [117,199], and deranged maturation
typically by failure to fuse with lysosomes [191–193].
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6. Late Endosomes and Amphisomes in Secretion of Amyloids
Regardless of the mechanism of amyloid import, the ionic and enzymatic milieu in late
compartments of the endosomal and autophagosomal pathway could promote generation of misfolded
or otherwise modified amyloids. Prelysosomal and lysosomal organelles have a low pH and
a redox environment, which differs from other organelles of the endosomal or autophagosomal
pathways. It is very possible that the chemical milieu of end stage organelles may promote
formation of proteotoxic species of contained amyloids by some form of conformational chemistry.
Thus, mildly acidic conditions greatly increase the propensity of α-synuclein to form aggregates
by increasing fragmentation and secondary nucleation events hardly detectable at neutral pH [12].
Different cholesterol- or tetraspanin-organized microdomains of the limiting membrane of the MVB
or the exosomes themselves may promote aggregation and proteopathic templating. For example,
glycosphingolipids GM1 and GM3 contained in exosomes support α-synuclein aggregation in the
lumen of the MVB [216]. It seems possible that qualitative conformational, chemical, or proteolytic
alterations of amyloid may increase their transmission, uptake, or propensity to catalyse seeded
aggregation after release from cells.
6.1. Unconventional Secretion
While it has been known for long that PrPsc and Aβ1–42 are released from nerve cells, it has
only more recently been recognized that also cytosolic amyloids can be secreted by one or more
unconventional mechanisms. Unconventional secretion refers to the cellular release of proteins, which
do not traffic through the normal ER-Golgi biosynthetic pathway (they lack a signal peptide), but
use other means to reach and traverse the cell surface. The number of proteins known to leave cells
unconventionally, as well as the number of unconventional pathways available for the purpose, are
increasing steadily [217]. Other mechanisms than exocytosis could conceivably be involved in the
secretion of amyloid protein from nerve cells including budding of microvesicles from the plasma
membrane, nanotubules, chaperone assisted secretion of amyloid [218,219], or escape through pores
formed in the membrane by amyloids [23], but here we will focus on mechanisms involving exocytosis
of vesicular intermediates.
In the case of α-synuclein, several groups have documented unconventional mechanisms
of secretion [28–30,32,33]. The group of Lee [32,33] were the first to describe unconventional
secretion of α-synuclein aggregates, and also later reported that secretion was upregulated by cellular
stress and depended on the aggregation state of α-synuclein. These authors proposed a vesicular
exocytosis-model of α-synuclein secretion.
If so, the nature of the secretory organelle remains uncertain. Different studies have suggested
early [31] or late endosomes [30] but without addressing the obvious topological barrier for crossing of
cytosolic amyloid into the lumen of the endosomal pathway. Entry does occur though, as α-synuclein
can be localized to lysosomal and prelysosomal compartments in the brain [198].
We believe that late endosomes and in particular amphisomes constitute attractive candidates
for the dissemination of amyloid by exocytosis. First of all, the ESCRT-mediated import of
ubuiqitinated cargo into ILVs in the case of late endosomes, or the direct uptake of cytosolic cargo
into autophagosomes by selective autophagy, mechanistically explains the presence of amyloid in the
organelle lumen. This is not counting chaperone-mediated autophagy, where the lysosomal membrane
protein LAMP2a directly imports α-synuclein into lysosomes [117,197,199], nor microautophagy where
cargo is imported into late endosomes [116]. Second, both late endosomes and amphisomes are known
to undergo physiological exocytosis, a process which could be enhanced under stressful or pathological
conditions [220]. Finally, the endosomal and autophagosomal pathways are linear pathways. Although
membrane and proteins can enter and leave the endosomal pathway in vesicular carriers at several
destinations along the maturation pathway, the bulk of the endosome or autophagosome continues to
the terminal fusion with lysosomes. Therefore, any dysfunctional organelle along the route will cause
an accumulation of incoming vesicles, which is often quite toxic to cells [177,192], and relief of cytotoxic
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burden requires, as a last resort of clearance, exocytosis of the accumulating organelle [29]. Because
amphisomes and late endosomes are the penultimate organelles before lysosomes, they are particularly
prone to exocytosis in the context of the omnipresent lysosomal deficiency noted in neurodegenerative
disease. In the following, we discuss the role of MVB/late endosome and amphisome exocytosis in the
secretion of amyloid.
6.2. Exocytosis of Amyloid by MVBs and Late Endosomes
MVB and late endosome exocytosis in mammalian cells is controlled by a number of small
GTPases, including Rab11 [221], Rab27A and B [222] and their effectors, as well as Rab35 [223].
Recently, Ras-related protein Ral (Ral)A/B has also been implicated. Ral overexpression effects a
centrifugal MVB distribution close to the plasma membrane [224], which is perhaps similar in action to
Rab11 [221]. The t-SNARE syntaxin-5 may work down-stream of Ral to mediate fusion [224], perhaps
in combination with the prevalent endosomal SNARE VAMP7, but the SNARE machinery required for
MVB and late endosome fusion with the cell surface remains ill defined.
6.2.1. MVB and Late Endosome Secretion of Aβ
Both PrP and APP are transmembrane proteins, and pathological alterations (PrP conversion
to PrPsc and APP cleavage) cause the extracellular exposure of PrPsc or the luminal release of
Aβ1–42 through exposure of APP to β- and γ-secretases. APP is known to shuttle between the
trans-Golgi network (TGN) and endosomes [225–227]. While β-site cleavage of APP is accepted to
occur in endosomes or on the cell surface, the precise localization of γ-secretase cleavage (within
the transmembrane domain of APP) is under debate and has been proposed to occur in the TGN,
biosynthetic vesicles [227], or in endosomes [225,226,228]. Assuming an endosomal origin of
γ-secretase activity, it is interesting to note that APP and products of β- and γ-secretase activity,
including Aβ1–42, can be localized to MVBs and exosomes [101,102,229,230], and the release of Aβ1–42
is increased by agents that prevent fusion with lysosomes [102]. As Aβ1–42 is produced and released
into the lumen of late endosomes, there is no requirement for autophagy to explain the luminal
disposition of amyloid and its secretion by exocytosis of late endosomes. Nevertheless, AD is
the neurodegenerative disease where accumulation of autophagosomes and amphisomes is most
conspicuous [231,232], and recently, autophagy has been tied to degradation and/or secretion of
Aβ1–42 in mouse models and cell culture studies [207,209,214]. This suggests that injured endosomes
containing amyloid may be specifically engulfed by autophagosomes [210,211], following endosomal
membrane permeabilization due to luminal oligomer or protofibril formation.
6.2.2. MVB and Late Endosome Secretion of α-Synuclein and Other Cytosolic Amyloids
Most amyloidogenic proteins associated with neurodegenerative disease are cytosolic proteins,
and any role of late endosomes in the extracellular release of these protein aggregates requires crossing
of topological membrane barriers.
In this respect, it has attracted attention that SOD, tau, and α-synuclein in mainly monomeric form
associate with exosomes [26,28,30,34,35,233,234]. Exosomes are attractive candidates for transmission
of amyloid species, because of their potential to fuse with the plasma membrane (or limiting endosomal
membrane) of the recipient target cell leading to the intra-cytosolic release of amyloid species
contained within the exosome lumen. Based on high ionic strength extraction, protease sensitivity,
or ultrastructural analysis, amyloid is in part enclosed in the lumen of these exosomes, implying
that amyloid, on the cytosolic aspect of the limiting membrane of MVBs, can be internalized and
enclosed by ILV budding. It should be stressed that very small amounts of total secreted amyloid
are associated with exosomes (<1%–2%) the great majority of released material consisting of soluble
amyloid in monomeric or aggregated forms [29,229,235,236]. Exosome association of α-synuclein may
depend on the cellular model as some groups, including our own, find no or very little association
with secreted exosomes [29,31,237]. PrPsc also associates with exosomes, and it has been shown
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that exosome-associated PrPsc is processed by unique N-terminal proteolysis [235,236]. Exosomal
fractions are capable of transmitting prion disease to cells in culture or to mice following intracerebral
injection [235,236], and transmission of α-synuclein oligomers is enhanced by exosomes in vitro [28].
Histopathological analysis of disease propagation in the brain of mice [87] or man [1,86] show that
amyloid transmission takes place along interconnected nerve fiber tracts indicative of trans-synaptic
transmission. Mechanistic data to support this contention is still entirely lacking, but it is worthwhile to
note that exosomes in other systems show propensity for trans-synaptic relay of protein factors. MVBs
and late endosomes are known to localize to both pre- and post-synaptic compartments [230,238–241],
and convincing evidence implicates an exosomal shuttle in the trans-synaptic delivery of wnt and
the wnt-binding protein Evi in the neuromuscular junction of drosophila [241,242]. Exosomal
transmission may also explain the experimental trans-synaptic transfer of tetanus toxin-conjugated
Green Fluorescent Protein (GFP) (which is sorted to the ILVs of MVBs) between connected neurons [243]
or the transmission of retrogradely transported trophic factors in between neurons [238]. The
concentration of MVBs in synaptic structures is responsive to exogenous stimulation [240], and
at least one study has demonstrated that exocytosis of MVBs and exosomes is regulated by nerve cell
activity following glutaminergic stimulation [244].
Despite this precedence, the entry of amyloid into ILVs is only rudimentarily described, perhaps
with the exception of one case, which we will describe below in some depth.
7. Neuronal Precursor Cell-Expressed Developmentally Downregulated 4 (Nedd4)-Mediated
Import of α-Synuclein into ILVs?
As ubiquitination is required for ESCRT cargo import, it is interesting that α-synuclein has been
recognized as a substrate of the cytosolic E3 ubiquitin-protein ligase Nedd4, which attaches K-63 linked
ubiquitin chains to the C-terminus of α-synuclein [245,246]. In yeast models of α-synucleinopathy
Nedd4 constitutes an important node, whose manipulation modifies toxicity of α-synuclein through
alteration of membrane trafficking [247,248], and Nedd4 over-expression has proven beneficial in small
organism and mouse models of PD [249].
Nedd family interacting protein 1 (Nfdip1) is an endosomal transmembrane adaptor protein,
which interacts with Nedd4 and expands the repertoire of substrates available for ubiquitination
by Nedd4. Nfdip1 localizes Nedd4 to late endosomal membranes, where Nedd4 also interacts
with Alix [250] and possibly TSG101 [251,252] both associated with the ESCRT-I complex. Nfdip1
is required for the Nedd4-mediated ubiquitination and degradation of α-synuclein [245] and is
secreted in exosomes [253]. In mammalian cells Nedd4-mediated relief of protein misfolding
cytopathology seemingly involves an enhanced degradation of α-synuclein in a process, which requires
the ESCRT complex [245,249] whereas amelioration of toxicity occurs without any alterations in cellular
α-synuclein accumulation in yeast [247]. More experiments are clearly needed to address how Nedd4
modulates α-synuclein metabolism.
Although Nedd4-mediated ubiquitination would drive the assimilation of α-synuclein into ILVs
of late endosomes, ubiquitin is not necessarily needed to accomplish import. Intriguingly, it has been
shown that the effect of higher-order oligomerization and membrane association is sufficient to confer
entry into ILVs of diverse proteins [106,254], and it is possible that aggregated α-synuclein, which
readily associates with membranes, may gain access to the lumen of ILVs by a similar mechanism
(see Figure 2).
Although the total volume of cytosol enclosed by exosomes is considerable, it is likely not a
mechanism for bulk disposal of cytosolic protein aggregates (size would be limiting), and is unlikely to
account for the up to 10% of the total cellular α-synuclein pool that can be released from neurons [29].
In addition, it is clear in animal models of synucleinopathy and AD that exosomes are not required
for the initiation of propagating inclusion body disease or amyloidosis, respectively, which can be
inoculated by injection of purely synthetic amyloid into the brain [72,80]. In fact, in animal models of
AD, the highest specific inoculating activity of proteopathy of fractionated brain tissue homogenates
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resides in the non-exosomal fractions [3]. Neither are exosomes required for the ability of nerve cells in
culture to internalize recombinant α-synuclein [36,40,72] although some studies have shown a higher
proficiency of exosome-mediated amyloid transfer than by fluid phase alone [28].
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Figure 2. Import of cytosolic α-synuclein into intraluminal vesicles of multivesicular bodies and
late endosomes. (Right) Nfdip1 recruits the E3 ubiquitin ligase Nedd4 to the limiting membrane
of multivesicular bodies and late endosomes. Neuronal precursor cell-expressed developmentally
downregulated 4 (Nedd4) ubiquitinates (Ub) α-synuclein, which thereby becomes a substrate of the
Endosomal sorting complex required for transport (ESCRT) machinery for import into intraluminal
vesicles (ILVs; exosomes upon secretion per convention). Secreted α-synuclein is not ubitiquitinated,
as ubiquitin is removed by ESCRT-IV before scission of the budding intralumi al vesicle. Alter atively
(Left), aggregated and lipophilic rot ins, o which amyloids confo m, can enter int ILVs by a
mechanism that is independent of the ESCRT machinery. The circumstances f import, and whether this
form of import involves alternative ceramide- or CD63-based forms of ILV formation, remain unknown.
8. Exocytosis of Amyloid by Amphisomes
Autophagosomes and amphisomes appear as highly relevant compartments of amyloid secretion.
Not only are cytosolic aggregates taken up directly by autophagy, thereby bypassing the topological
barrier to vacuola elements, but amphisome can lso undergo physiological exocytosis to release
their contents [220,255], a process aggravated by l sosomal deficiency. Physiological unconven ional
secretion of protein factors by autophagy (dubbed autosecretio ) was first demonstrated for Acetyl
coenzyme A (Acyl-CoA) binding protein from yeast [255–257], and later it was shown that Interleukin-1
β (IL-1β) and High mobility box group 1 (HMBG1) are secreted by a similar mechanism in mammalian
cells [220].
Autosecretion of IL-1β in human cells and Acyl-CoA binding protein in yeast depend on multiple
Atg proteins and Golgi reassembly stacking protein (GRASP), a normally Golgi-localized protein,
which also affects early steps in the autophagy pathway [128,220,255–257]. GRASP is a presumed
membrane tethering factor, which not only participates in autosecretion but also in other forms of
unconvention l secret on including t afficking of certain m mbrane proteins to the cell surface [128,258].
In yeast the ESCRT-I subunit Vps23 (TSG101 homologue) and ESCRT-III subunit Vps4 are also required
for autosecretion [255,257]. Whether this reflects that ESCRT components are directly involved in the
autosecretory process or a requirement for an uninterrupted flow through the endosomal pathway for
amphisome formation remains to be clarified. RalA/B, which promotes MVB/late endosome fusion
with the plasma membrane [224], is also present on autophagosomes [259], but its involvement in
exocytosis of amphisomes is unknown.
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Secretion of α-Synuclein by Exophagy
We have recently shown that α-synuclein in NGF-differentiated cathecholaminergic PC12 neurons
is taken up by autophagy, and that this process is enhanced by aggregation of α-synuclein through
co-expression of the PD-related protein TPPP/p25α [29,260]. TPPP/p25α also mimics aspects of
lysosomal dysfunction by inhibiting final fusion of amphisomes with lysosomes by blocking HDAC6
activity [29]. This causes accumulation of amphisomes and an increased secretion of α-synuclein
to the medium, which could be decreased by knocking-down Rab27A required for secretion of late
endosomal elements [222]. We find that the bulk of α-synuclein monomer and high molecular weight
aggregates are soluble and only a minute quantity of monomer is associated with exosomes [29].
In several different forms of unconventional secretion, a requirement for Rab8 has been
noted [220,258]. The role of this small GTPase in unconventional secretion and autosecretion remains
unsettled, but in other contexts Rab8 is involved in the vectorial vesicular trafficking to areas of
polarized plasma membrane growth [261–264] and vesicle docking to acceptor membranes upstream
of the SNARE machinery in fusion reactions [262]. Rab8 interacts with synaptotagmins also engaged by
Rab27A [265]. Our finding that Rab8 colocalizes with mature autophagosomes and amphisomes, and
greatly increases exophagosomal α-synuclein release concurrent with an amelioration of cytopathology
and nerve cell survival [29], therefore offers a possible additional explanation to the suppressive effect
of Rab8 on α-synuclein-induced toxicity in yeast, small organism models and mammalian cells in
culture [266].
In yeast, plasma membrane-localized exocytic SNARE’s Sso1 and Sec9p (mammalian homologues
Syntaxin-1 and SNAP25, respectively) are required for exocytosis of amphisomes [255,267]. However,
the very same SNAREs are also required early in the autophagosomal pathway [268] making the
effect of SNARE deficiency on autosecretion difficult to dissect from autophagy initiation. Further
work is necessary to conclusively establish the sets of SNAREs that mediate exophagy in yeast and
mammalian cells.
9. Lysosomal Deficiency
Lysosomal dysfunction and deficiency is a general cytopathic feature of neurodegenerative disease,
and we have already discussed how this increases exocytosis of prelysosomal elements. In the following
we will examine known types of lysosomal deficiency, exemplified mainly by identified genetic risk
factors for the development of PD, and discuss lysosomal exocytosis. However, first we will high-light
the intimate physiological relationship between lysosome dynamics and the autophagosomal pathway.
9.1. Lysosomes and Autophagy Are Closely Interrelated
Lysosomes and autophagy reciprocally affect each other [269], and many lysosomal and
autophagosomal gene products are regulated coordinately by the master transcription factor EB
(TFEB) [270,271]. TFEB is under normal conditions retained in the cytosol or bound to the limiting
membrane of lysosomes, but following stress or starvation TFEB translocates to the nucleus where
it promotes transcription of a network of genes required for autophagy and lysosomal function
and regeneration [271]. Translocation requires that TFEB phosphorylation by active extracellular
signal-regulated kinase (ERK) [271] or mTOR [272] is relieved in response to lysosome deficiency, low
concentration of luminal amino acids (see below), or autophagy induction.
The mTOR complex localizes to the limiting membrane of lysosomes, and in an intricate
mechanism, that has luminal amino acid sensing by the V-ATPase at its core, amino acid efflux
from lysosomes in part governs its activation status [109,273,274]. mTOR activity is also regulated by
the subcellular distribution of lysosomes, which are more peripheral in basal conditions but move
towards the nucleus (and the microtubule-organizing center (MTOC)) in response to nutrient starvation
correlating with an increased pH and mTOR activation [275]. It remains to be established how these
results align with the recent demonstration that peripheral lysosomes are relatively devoid of Rab7
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and V-ATPase, resulting in a higher pH [276]. In a distinct mechanism, mTOR reactivation at the
termination of an autophagosomal response or following protracted starvation regulates the tubular
reformation of (proto)lysosomes from autolysosomes [277].
9.2. Mechanisms of Lysosomal Deficiency in Neurodegenerative Disease
Dysfunction of the autophagolysosomal degradation pathway is a common feature of the
genetic synucleinopathies [278], and there is little doubt that lysosomal deficiency is an important
cytopathological mechanism in neurodegenerative disease [109,215,279–282].
There are many conceivable ways lysosomes can fail to perform their normal duty as final
degradation apparatus of endosomal and autophagosomal cargo (See Figure 3).
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Figure 3. Mechanisms of lysosomal deficiency. (1) Normal delivery of the 50+ lysosomal acid
hydrolases can become compromised by the lack of individual functional hydrolases or more generally
by the derangement of Trans-Golgi network (TGN)-endosome trafficking affecting retromer (VPS35
mutations) function and its client Mannose-6-phosphate receptor (M6PR), the receptor for sorting of
many hydrolases from TGN to the endosome; (2) In some lipid storage diseases SNAREs, required for
entry of autophagosomes into the endolysosomal system, become “trapped” in cholesterol-enriched
microdomains of lipid-laden late endosomes/lysosomes; (3) Proton and calcium fluxes are also affected
in Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Presenilin (PSEN) mutations compromise
sorting and/or function of the v-Adenosine Triphosphatase (ATPase) leading to relative alkalisation of
the lysoso e with reduced proteolysis. PSEN utations also indirectly affect calcium efflux through
mucolipin channels. Th lysosomal phenoty contributed by Leucine-rich repeat kinase 2 (LRKK2)
mutations can be rescued by Two-pore channel (TCP2) calcium channel knock-down; (4) ATP13A2
positively regulates ILV f rmation in late endosomes, and ATP13A2 mutations confer reduced
luminal acidification and proteolysis that can be rescued by overexpression of synaptotagmin 11;
(5) Autolysosome reformation is inhibited by gene products associated with neurological disease
including clec16A, spastizin and spatacsin, and PI4K.
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9.2.1. Deficiency of Degradative Hydrolases
First of all, the delivery of mature degradative hydrolases to the lysosomal compartment may
be compromised, or specific acid hydrolases may be absent all together. In the latter case different
lysosomal storage disorders may arise. For example Gaucher’s disease caused by β-glucocerebrosidase
deficiency, which incidentally constitutes the strongest genetic risk factor identified to date for
development of PD. Even though genetic hydrolase deficiency affects only a single or few substrate(s),
secondary lysosomal defects arise due to accumulation of substrate, and may extend to also involve
autophagosomal pathways [237,283,284].
Several genes identified in large genome-wide association studies as being linked with
development of PD are known or have proven to be involved in vesicular trafficking. Thus, VPS35
(PARK17) is a subunit of the retromer, an endosomal trimeric cargo-recognition protein complex
composed of VPS26, VPS29 and VPS35, involved in recycling of receptors from late endosomes to the
TGN. Retromer dysfunction was first described in AD [285], while continued studies are required to
fully explain how VPS35 mutations result in α-synuclein accumulation, loss of dopaminergic nerve
cells, and locomotor problems in mouse [286] or drosophila [286] models of PD. Client proteins of
the retromer include M6PR [287], LAMP2a [286], and APP [225]. It is therefore not surprising that
functional deficiency of VPS35 impairs lysosomal proteolysis, as acid hydrolase delivery would be
expected to diminish due to sequestration and increased degradation of M6PR in endolysosomes [287].
M6PR is down regulated in brains from α-synuclein overexpressing animal models and in PD patients
with early diagnosis [288]. Transport of hydrolases from the TGN to endosomes is directly affected by
α-synuclein over-expression. Thus α-synuclein inhibits the activity of Rab1, a small GTPase necessary
to promote biosynthetic vesicle transport from the TGN, in both yeast, small animal models, and
human cells [266,289,290].
Also, autophagy is adversely affected by VPS35 deficiency. The relative lack of LAMP2a decreases
chaperone-mediated autophagy [286], and macroautophagy is impeded by the failure to recruit the
actin-organizing protein WAS protein family homolog 1 (WASH) to autophagosomes and endosomes
via VPS35 binding [291]. Parkinsonian VPS35 mutations may both interfere with the sorting function
of VPS35, as well as displace the retromer from late endosomes to cytosol [292,293].
9.2.2. Sequestration of Fusion Machinery Components
SNAREs required for fusion of amphisomes or late endosomes with lysosomes may not be
available. An example is several lysosomal lipid storage disorders, where autophagy is known to be
impeded by a failure to enter the endolysosomal system due to the lack of SNAREs to catalyze the
fusion reaction [294]. Instead, SNAREs are aberrantly sequestered in cholesterol-enriched domains on
the limiting membrane of cholesterol-engorged late endosomes and lysosomes [295].
9.2.3. Lysosomal Proton and Calcium Imbalances
The v-ATPase is responsible for proton pumping into the endolysosomal lumen to lower the
pH to 4.5–5 required for optimal catalytic activity of the 50+ different lysosomal hydrolases.
In AD, where accumulation of autophagosome vacuoles is prominent [231], it has recently
been proposed that Presenilin (PSEN), mutations of which cause familial AD, is required for
proper acidification of lysosomes [215]. Mechanistically, PSEN was found to be required for proper
N-glycosylation of a subunit in the v-ATPase, which mediates its sorting from TGN to lysosomes.
Others have opposed this conclusion and find that PSEN mutations in drosophila cause calcium
efflux from lysosomes through undescribed mechanisms [296]. Although calcium efflux (through
non-selective cation mucolipin channels) is also true in mammalian cells, only correction of lysosomal
pH, not calcium concentration, ameliorates lysosomal proteolysis and block in the autophagosomal
pathway [297].
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Lysosomal calcium homeostasis is also affected in PD. Leucine-rich repeat kinase 2 (LRRK2;
PARK8) is a large protein with both kinase and GTPase activity. It suppresses autophagy in normal
conditions [298,299], but mutations have been tied to alterations in late endosomal membrane
trafficking [300] and the formation of pathologically large lysosomes [301,302]. Vps35 overexpression
rescues the pathological phenotype of LRRK2 mutations in drosophila models [303]. The lysosomal
phenotype is specifically mediated through cation two-pore channels (TPCs) that gate calcium in the
lysosome; silencing of TPC2 corrects the LRRK2 phenotype [301].
9.2.4. ATP13A2
ATP13A2 (PARK9) is a lysosomal type 5 P-type ATPase that takes part in the control of lysosomal
acidification. ATP13A2 has been linked to autosomal recessive early-onset parkinsonism, pyramidal
degeneration and dementia. Cells carrying deficient ATP13A2 have impaired lysosomal acidification,
reduced degradation of lysosomal substrates, and diminished clearance of autophagosomes [304,305].
ATP13A2 localizes to lysosomes and MVBs where its activity is supported by binding inositol lipids
in the limiting membrane [306]. ATP13A2 has been shown to positively regulate exosome biogenesis
through interactions with the ESCRT machinery, and overexpression of ATP13A2 increases the content
of α-synuclein secreted in exosomes several-fold [233,234]. The common LRRK2 G2019S mutation
causes formation of enlarged lysosomes with a reduced luminal pH, and an increased complement
of ATP13A2 in the membrane [302]. ATP13A2 depletion negatively regulates synaptotagmin 11
(SYT11), another putative PD-associated gene, at both transcriptional (through TFEB regulation) and
post-translational levels [307]. Overexpression of SYT11 rescues the ATP13A2 lysosomal phenotype,
and conversely, SYT11 knock-down is sufficient to induce lysosomal dysfunction and impaired
degradation of autophagosomes.
9.2.5. Faulty Lysosome Regeneration
Another mode of lysosomal deficiency arises when autolysosomes fail to regenerate at the end
of the autophagosomal response. Normally, protolysosomes are regenerated from autolysosomes
in an mTOR-dependent mechanism [277]. At this point mTOR reactivation is required, and it
has been described that spinster, a putative carbohydrate permease in lysosomes, is required for
reactivation of mTOR and initiation of lysosome reformation following starvation [308]. Slender
tubules shaped by kinesin motor force [309] are formed and then pinched off the limiting membrane to
form protolysosomes in a process requiring clathrin and phosphatidylinositol-4,5-bisphosphate [310].
Phosphatidylinositol-4-phosphate (PI4P) can serve as precursor for the latter and is generated by
PI4IIIK. However, PI4IIIK specifically seems to affect the membrane fission step of tubule formation
suggesting a role for PI4P in this process [311].
Recently, Clec16A, a protein associated with development of multiple sclerosis, has been shown
to be required for autolysosome function in mouse models: in the absence of Clec16A both neuronal
endocytosis and autophagy initiation are unperturbed, however, autolysosomes accumulate due to
lacking regeneration of protolysosomes [312]. In particular, Purkinje nerve cells were affected.
Along the same lines, the two most common autosomal recessive hereditary spastic paraplegia
gene products, the SPG15 protein spastizin and the SPG11 protein spatacsin, are both required for
autophagic lysosome reformation [313,314]. Knock-out of these genes in mice cause accumulation of
autolysosomes correlating with depletion of functional lysosomes, and leading to the development of
a paraplegia-like phenotype with degeneration of corticospinal axons and loss of cortical neurons and,
again, Purkinje cells.
9.3. Exocytosis of Amyloid by Lysosomes
It was once thought that lysosome exocytosis was the prerogative of certain specialized cell types
containing so called lysosome related organelles. However, it is now recognized that all cells have
the capacity for lysosome exocytosis in a calcium-dependent manner [315,316], and that lysosomal
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exocytosis can function as an integral process in excretion of undesirable and toxic materials [317].
The lysosomal fusion reaction with the plasma membrane depends on calcium sensor synaptotagmin
VII [318] and VAMP7 on lysosomes, which binds syntaxin4 and SNAP23 in the plasma membrane [319].
It has been shown that TFEB (transcriptionally) promotes lysosomal exocytosis by increasing the
population of plasma membrane-proximal lysosomes, and by increasing lysosomal calcium efflux
through mucolipin channels [320]. Overexpression of TFEB caused an amelioration of lysosomal
storage disease presumably by clearance of accumulated material through exocytosis. However, the
conclusion is difficult to draw because TFEB also boosts the autophagolysosomal system in general.
The recent demonstration in mouse models of AD that congregation of axonal lysosomes with a greatly
reduced content of acid hydrolases surround amyloid plaques at all stages of formation [321] sustains
the idea that lysosome exocytosis also in neurodegeneration is a mechanism of excretion of amyloid.
10. Microglia in Disease Dissemination
There is a huge body of in vitro and in vivo evidence demonstrating that neurodegenerative
diseases are not cell-autonomous, but depend on the recruitment and activation of glia cells, first
and foremost microglia, which are essential for progression of brain disease in animal models of PD
and other brain diseases [322]. There is microglia activation before manifest nerve cell loss in man,
primate, and mouse models, and amyloids in oligomeric or insoluble format are known to activate
resident microglia through a variety of pattern recognition receptors including RAGE, CD36, TLRs, and
FcγR’s [52,53,57,58,323–325], which drive classical activation of microglia (inflammation and pathogen
combat). The ensuing chronic inflammation of the brain and/or cessation of neurotrophic support
instill a milieu, which aggravates nerve cell death and promotes disease progression while impairing
neuroregeneration [322,326].
Recently, potential new facets of microglia contribution to disease progression have been proposed.
Thus, we have shown in vitro that microglia activated by conditioned medium from synucleinopathic
neurons in culture (or LPS) increase α-synuclein secretion from the neurons [327]. While the microglia
factors that mediate this effect are unknown, the ensuing neuronal hyper-secretion of α-synuclein
depends on c-Jun N-terminal kinase (JNK) activation in the nerve cells [327]. Additionally, microglia
might potentially ‘qualitatively enrich’ amyloids for their ability to transmit misfolding disease. Thus,
it has recently been shown that microglia internalize tau by endocytosis, and then, subsequent to
immune cell activation (by LPS), release tau contained within the lumen of exosomes [328]. In a mouse
model of tauopathy propagation from entorhinal cortex to the dentate gyrus both microglia depletion
and inhibition of exosome formation inhibits spread of cytopathology. What the study does not address
is how internalized, soluble tau escapes from endosome to cytosol, is seemingly ubiquitinated, and
then taken up by ceramide-based (and therefore ubiquitin-independent) ILVs before release by late
endosome exocytosis. More work is clearly needed to understand how microglia can forward brain
disease by promoting seed dissemination.
11. Aging, Proteostasis, and Autophagy
It is clear that aging constitutes a major predisposing factor for the development of protein
misfolding disease. Remarkably, in Caenorhabditis elegans (C. elegans), several hundred proteins undergo
a transition to insoluble form in aged worms [329,330]. Like human amyloids these proteins adopt a
parallel β-pleated sheet conformation in their aggregated form, and a relatively high proportion of
them are involved in energy production and translation, and have an effect on longevity. It is not known
whether protein aggregation is a cause or an effect of normal aging, but interestingly, in the nematode
models insolubility and aggregation could be circumvented by reduced insulin/IGF-1-signaling [330]
known to extend life span. Reducing the propensity for protein aggregation chemically by treating
C. elegans with thioflavin, which binds many amyloids, extends lifespan and slows ageing in processes,
which depend on molecular chaperones, autophagy, and proteasomes [331].
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Conversely, there is a large body of evidence to suggest that upregulation of the cellular
degradative machinery, not only prevents protein aggregation, but also prevents neurodegenerative
disease, and in some cases extends life span. Dietary restriction extends life span of organisms
from worms to mammals by reducing insulin/IGF-1-signaling, mTOR activity, and mitochondrial
respiration. In this respect, it is interesting to note that suppression of crucial autophagy genes in
C. elegans cancels the effect of all known paradigms of life span extension [332]. mTOR also regulates
life span of mammalian organisms. In mouse models rapamycin, an inhibitor of mTOR, and thereby
activator of autophagy, extends life span of mice of both genders, even when treated with the drug
quite late in life [333].
In general, protein homeostasis is perturbed across different tissues of aging humans [334].
A diminished capacity of the major degradative systems, the proteasome and the autophagolysosomal
pathway [335,336], shifts the balance between production and clearance of endogenous noxious
materials. The resulting accumulation of proteotoxic waste eventually ramifies to affect biosynthesis
with development of ER stress and induction of the unfolded protein response (UPR) [337]. Not many
studies have examined the workings of the autophagosomal system in the aging human brain.
However, there is consensus that autophagosomal flux is reduced compared to young individuals
as transcription of key players of the autophagosomal pathway including beclin-1, ATG5, and
ATG7 is reduced [338]. AD stands out as the brain disease with the most prominent concentration
of autophagosomal vacuoles [231]. In accordance herewith, many autophagy-related proteins
participating on all levels of the autophagosomal pathway are upregulated in AD brain compared
to age-matched controls [232,338]. An exception is beclin-1, which is down-regulated in AD
brain [214,232,339]. In PD there is no information on the macroautophagosomal system, but
chaperone-mediated autophagy is depressed by the down-regulation of LAMP2a and Hsc70 [340].
12. Therapeutic Implications
The transmission model of neurodegenerative disease propagation opens up for entirely new
ways of thinking about therapeutic intervention. Evidence from animal model experiments indicates
that upregulation of autophagy is beneficial in different types of neurodegenerative disease. In mouse
models of PD, overexpression of beclin-1 ameliorates disease by correcting autophagosomal aberrations
induced byα-synuclein expression [339]. In AD models, where beclin-1 expression is reduced, lentiviral
overexpression of beclin-1 has also been reported to rescue cytopathology and reduce both intracellular
and extracellular amyloid pathology in APP transgenic mice. Conversely, mice heterozygous for
beclin-1 shows accelerated neurodegeneration [214].
The therapeutical promotion of autophagy alone is, however, most likely not a universal
mechanism for correction of cellular pathology by misfolding. In the 5xFAD mouse model of AD,
lysosomal dysfunction (acidification), Aβ deposits, and cognitive deficits were reduced by a GSK-3
inhibitor under conditions of mTOR reactivation and thus decreased autophagy [279]. Similarly,
although perhaps coincidental, several drugs in clinical trial for treatment of AD actually reduce
autophagosomal flux [338]. Finally, tissue specific and conditional knock-out of ATG7 in mouse
models of AD decreases extracellular Aβ plaque burden by decreasing exocytosis of amyloid [209].
In particular, AD stands out as a neurodegenerative disease where autophagy enhancement could
turn out to be problematic despite positive results gained with beclin overexpression in one mouse
model of AD [214]. There is a forming consensus that the major cytopathic problem in AD is lysosomal
clearance of autophagosomal cargo, rather than the workings of the autophagosomal pathway itself.
By comparison of nondemented controls with early or late stage AD, evidence has been provided that
the autophagosomal pathway is induced in CA1 pyramidal neurons of hippocampus in AD cases [232].
Although lysosomal biogenesis is also upregulated, the lysosomal capacity is exceeded by the inflow
of autophagosomes causing the pronounced accumulation of autolysosomal vacuoles characteristic of
AD [231,232].
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Therefore, induction of autophagy is only relevant in disease states that do not involve lysosomal
deficiency, as accumulation of prelysosomal elements would be exacerbated drastically and thereby
toxicity increased.
Modulation of TFEB, the major transcriptional regulator of lysosomal and autophagosomal genes,
to coordinately upregulate both autophagy and lysosomal biogenesis and recycling pose an appealing
possibility. Since TFEB coordinately regulates both the autophagosomal pathway as well as lysosomal
biogenesis there is a good chance that the plasticity of the network will be able to accommodate
differences in cellular pathology in between different amyloids and on different patient backgrounds.
TFEB has shown efficacy in suppressing amyloid toxicity in C. elegans as well as murine models of
PD [341,342], and of AD and tauopathy [343]. Incidentally, TFEB overexpression increases longevity
of C. elegans [341], again high-lighting the presumed, but not proven, causal correlation between
autophagy, protein homeostasis, and life span. However, these data derived from animal models
of neurodegenerative disease may not allow sufficient time for potential adverse effects of TFEB to
be registered. A major concern in the human situation remains the propensity of TFEB to increase
lysosomal exocytosis [320], which would support the amyloid dissemination step of transmission.
13. Conclusions and Perspectives
Lysosomal dysfunction, whether a primary or secondary deficiency, is an integral cytopathological
trait of neurodegenerative diseases. While the mechanisms that precipitate lysosomal dysfunction
may vary, the consequence is the same: a reduced proteolysis of undesirable cargo, whether caused by
deficiency of acid hydrolase activity, or by a failure to fuse with incoming prelysosomal elements.
The resulting accumulation of amphisomes and/or late endosomes will eventually result in either
cell death, or, as a last resort, the exocytosis of the accumulating organelle. Exocytosis of amphisomes
relieves α-synucleinopathy in cultured cells, and increasing exocytosis, for example by expression
of Rab8, further decreases synucleinopathic toxicity [29]. In storage disorder diseases, exocytosis of
lysosomal elements ameliorates disease [320].
We have devoted a relatively large body of text to describe the SNAREs and regulatory factors
that govern either the fusion of amphisomes/late endosomes with lysosomes, or the alternative fate,
fusion with the plasma membrane to release contents to the surroundings. There is little doubt that this
bifurcation in membrane trafficking pathways will be an important node for therapeutic modulation
of amyloid clearance. The interesting results achieved by the group of Lindquist [247] lends credence
to the belief that drugs that modulate this bifurcation can be identified: the unbiased library screen
identification of small chemicals that affect the membrane trafficking node controlled by Nedd4,
ameliorates synucleinopathy in yeast and mammalian neurons.
Very likely, nerve cells are able to concomitantly secrete both monomeric, but potentially modified,
amyloid enclosed in exosomes, and soluble amyloid in the form of proteotoxic oligomers and
aggregates [21]. In the future, it will be important to determine which of these species are most
relevant for inoculation and disease propagation to devise focused therapeutic strategies.
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Abbreviations
Aβ Amyloid β
Acyl-CoA Acetyl coenzyme A
AD Alzheimer’s Disease
AMPK AMP-activated protein kinase
APP Amyloid precursor protein
ARF6 Adenosine diphosphate-ribosylation factor 6
ATG Autophagy-related
ATPase Adenosine Triphosphatase
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BAG Bcl-2 associated athanogene
C. elegans Caenorhabditis elegans
ER Endoplasmic reticulum
EPG5 Ectopic P-Granules Autophagy Protein 5 Homolog
ESCRT Endosomal sorting complex required for transport
FcγR Fc receptors for IgG
GABARAP GABA(A) receptor-associated protein
GFP Green fluorescent protein
GRASP Golgi reassembly stacking protein
GTPase Guanosine triphosphatase
HDAC6 histone deacetylase 6
HMBG1 High mobility group box 1
HOPS Homotypic fusion and protein sorting
Hrs Hepatocyte growth factor-regulated substrate
ILV Intraluminal vesicle
IL-1β Interleukin-1 β
LAMP Lysosome-associated membrane protein-2
LC3 Microtubule-associated proteins 1A/1B light chain 3B
LRRK2 Leucine-rich repeat kinase 2
M6PR Mannose-6-phosphate receptor
MTOC Microtubule-organizing center
mTOR Mechanistic target of rapamycin
MVB Multivesicular body
NBR1 Neighbor of BRCA1 gene 1
NDP52 Nuclear domain 10 protein 52
Nedd4 Neuronal precursor cell-expressed developmentally downregulated 4





PLEKHM Pleckstrin homology domain-containing family M
PSEN Presenilin
PrP(sc) Prion protein (scrapie associated)
RAGE Receptor for advanced glycation endproducts
Ral Ras-related protein Ral
RILP Rab interacting lysosomal protein
RUBICON Run domain Beclin-1-interacting and cysteine-rich domain-containing protein
SNAP Synaptosomal-associated protein
SNARE Soluble N-ethylmaleimide-sensitive factor-attachment protein receptors
SOD Superoxide dismutase
STAM Signal-transducing adaptor molecule
SYT11 Synaptotagmin 11




TPPP Tubulin polymerization-promoting protein
ULK The ser/thr-kinase uncoordinated family member-51-like kinase
UVRAG UV radiation resistance-associated gene protein
Vam7 Vacuolar morphogenesis protein 7
VAMP Vesicle-associated membrane protein
Vti1b Vesicle transport through interaction with t-SNAREs homolog 1B
(C-)VPS (Class C-) Vacuolar protein sorting-associated protein
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